QDEL logo

QUIDELORTHO CORP

QDELNASDAQ
πŸ† #2418 by market capEarnings Nov 3 Β· PostUS Equity
$13.76β–Ό $0.25 (βˆ’1.78%)
πŸŒ™ After hours$13.76β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track QDEL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.8%
7dβ–² 0.2%
14dβ–² 6.5%
30dβ–² 30.6%
ytdβ–Ό 51.9%
1yβ–Ό 48.6%
🏦Market Cap
$944M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-1.9%
Declining
πŸ“ŠGross Margin
44.6%
Healthy
πŸ’΅FCF Margin
-7.9%
Thin
βš–οΈP/S Ratio
0.4x
Cheap
Otter Score
56
Fair

Trading Snapshot

Day Range
$13.63 – $14.26
52-Week Range
$9.92 – $35.58
Volume (shares)
1,508,989
Avg Volume (shares)
β€”
Shares Outstanding
68.6M
Next Earnings
2026-11-03

Fundamentals Snapshot

Annual Revenue
$2.73B
Last Q Revenue
$631M
P/E Ratio
-0.9
P/S Ratio
0.4x
EPS (TTM)
$-15.35
Dividend Yield
0.00%
Dilution (1yr)
+0.9%
QDEL logo

QUIDELORTHO CORP

QDEL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.7Bβ–Ό βˆ’1.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
46.7%β–² +1.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$919Mβ–Ό βˆ’53.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$83Mβ–Ό βˆ’26.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
67.8Mβ–² +0.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$2.7Bβ–Ό βˆ’$81M YoY
StockOtter Β· stockotter.space

About QUIDELORTHO CORP

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
56/100

Analyst Ratings

β“˜
Consensus
Sell
8 analysts
Strong Buy0
Buy1
Hold3
Sell2
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

PRNewsWireΒ·12h ago

Transforming Data Into Actionable Insights in the Lab

SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 62 of its Science Bytes podcast, exploring best practices in AI and

PRNewsWireΒ·9d ago

QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)Β ("QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will issue a press release to report its financi

Defense WorldΒ·12d ago

Financial Analysis: Elutia (NASDAQ:ELUT) & QuidelOrtho (NASDAQ:QDEL)

QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Elutia (NASDAQ: ELUT - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength

PRNewsWireΒ·14d ago

QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board o

Zacks Investment ResearchΒ·15d ago

Reasons to Add QuidelOrtho Stock to Your Portfolio for Now

QDEL's strong Q2 results, diversified product portfolio and cost-saving initiatives bolster its growth prospects despite persistent weakness in respiratory demand.

PRNewsWireΒ·21d ago

Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p